- SKYZoster®’s cumulative sales expected to reach 100 billion KRW this year

- SKYZoster’s market share reached out to almost 50%

SK bioscience announced on the 12th that the company’s self-developed herpes zoster vaccine, ‘SKYZoster ®´ has been sold more than 1 million doses in the Republic of Korea as of December last year. The achievement was reached only two years after since the launch of the product.

According to the drug market research firm IQVIA, SKYZoster ®’s total market share for herpes zoster vaccine in the fourth quarter of last year reached 47.4%.

As the safety or efficacy of vaccination has been verified in the market, the vaccination rate of SKYZoster is expected to be increased in the future.

With the SKYZoster ´’s quick settlement in the market, SK bioscience plans to expand the market share to the global market including Southeast Asia this year.

Jaeyong Ahn, CEO of SK bioscience said, "As population aging is being accelerated, interest in herpes zoster vaccine will increase. We will reach out to the world with a commitment to promote human health.”